Dural venous sinus thrombosis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Dural venous sinus thrombosis (DVST), also called cerebral venous sinus thrombosis (CVST), is a rare type of stroke that occurs when a blood clot forms in one of the dural venous sinuses—the large veins that drain blood from the brain back to the heart. Because the clot blocks normal venous outflow, pressure builds up in the brain, leading to swelling, hemorrhage, or ischemia.

DVST can affect anyone, but certain groups are more commonly diagnosed:

• Women of child‑bearing age (particularly during pregnancy, the puerperium, or while taking oral contraceptives).
• Patients with inherited or acquired hypercoagulable states (e.g., Factor V Leiden, antiphospholipid syndrome).
• Individuals with systemic illnesses such as cancer, inflammatory bowel disease, or severe infections.
• People who have undergone head trauma or neurosurgical procedures.

Although exact worldwide incidence is difficult to capture, epidemiologic studies estimate 3–4 cases per million adults per year in the United States and Europe, with a higher incidence (up to 12 per million) reported in some Asian populations <sup>[1][2]</sup>. Women account for roughly 70 % of cases, largely due to hormonal and pregnancy‑related risk factors.

Symptoms

Symptoms of DVST are highly variable and may develop over hours to weeks. The most common presentations include:

• Headache – often new‑onset, persistent, and may be diffuse or localized; can worsen when lying down or with Valsalva maneuvers.
• Focal neurologic deficits – weakness or numbness in the face, arm, or leg; difficulty speaking (aphasia) or understanding language.
• Seizures – reported in 30‑50 % of patients; may be focal or generalized.
• Visual disturbances – blurred vision, double vision, or papilledema from increased intracranial pressure.
• Altered mental status – confusion, lethargy, or coma in severe cases.
• Nausea and vomiting – often related to raised intracranial pressure.
• Neck stiffness or photophobia – can mimic meningitis.
• Fever – low‑grade fever may be present, especially when infection is an underlying trigger.

Because the clinical picture overlaps with many other neurological conditions, a high index of suspicion is crucial, especially in patients with known risk factors.

Causes and Risk Factors

DVST results from a combination of vessel wall injury, altered blood flow, and a hypercoagulable state—known as Virchow’s triad. The most common etiologies are:

Pro‑thrombotic (hypercoagulable) conditions

• Inherited thrombophilias: Factor V Leiden, prothrombin G20210A mutation, protein C/S deficiency, antithrombin deficiency.
• Acquired disorders: antiphospholipid antibody syndrome, elevated homocysteine, myeloproliferative neoplasms.
• Cancer (especially adenocarcinomas of the lung, pancreas, and gastrointestinal tract) and its chemotherapy.

Hormonal influences

• Oral contraceptives or hormone replacement therapy.
• Pregnancy & the first six weeks postpartum (hypercoagulable state, venous stasis).

Inflammatory and infectious causes

• Systemic infections (e.g., sepsis, COVID‑19) that provoke cytokine storms.
• Local infections: otitis media, mastoiditis, sinusitis, or facial cellulitis spreading to the cavernous sinus.
• Autoimmune vasculitis (e.g., systemic lupus erythematosus, Behçet disease).

Mechanical or traumatic factors

• Head trauma or skull fractures.
• Neurosurgical procedures, lumbar puncture, or dural puncture.
• Dehydration and prolonged immobility (e.g., long‑haul flights, hospitalization).

Other notable risks

• Obesity (BMI ≥ 30 kg/m²) – associated with increased clotting factors.
• Smoking.
• Elevated serum estrogen levels (e.g., in IVF protocols).

In up to 30 % of cases, no clear provoking factor is identified; these are termed “idiopathic” DVST.

Diagnosis

Timely diagnosis hinges on recognizing the symptom pattern and rapidly obtaining appropriate neuro‑imaging. The diagnostic work‑up typically proceeds as follows:

Initial clinical assessment

• Detailed history focusing on headache characteristics, recent pregnancy, medication use, and known thrombophilias.
• Neurologic examination for focal deficits, papilledema, or signs of increased intracranial pressure.

Laboratory studies

• Complete blood count, basic metabolic panel, and coagulation profile (PT/INR, aPTT).
• Targeted thrombophilia screen (if not emergent) – Factor V Leiden, prothrombin mutation, protein C/S, antithrombin, antiphospholipid antibodies, homocysteine.
• Inflammatory markers (CRP, ESR) and infection work‑up if clinically indicated.

Imaging modalities

1. Magnetic Resonance Venography (MRV) – the gold standard; visualizes the dural sinuses and identifies filling defects. Often combined with conventional MRI sequences (T1, T2, FLAIR) to detect hemorrhage or edema.
2. Computed Tomography Venography (CTV) – widely available, fast, and highly sensitive; useful in emergent settings when MRI is contraindicated.
3. CT Scan (non‑contrast) – may show hyperdense thrombus (the “dense triangle sign”) or secondary hemorrhage, but is less specific.
4. Digital Subtraction Angiography (DSA) – reserved for equivocal cases or when endovascular intervention is planned.

Additional assessments

• Fundoscopic exam for papilledema.
• Electroencephalogram (EEG) if seizures are suspected.

Treatment Options

The therapeutic goal is to recanalize the thrombosed sinus, prevent clot propagation, treat the underlying cause, and manage complications such as seizures or intracranial hypertension.

Anticoagulation – first‑line therapy

• Initial phase: Low‑molecular‑weight heparin (LMWH) (e.g., enoxaparin 1 mg/kg SC q12h) is preferred because of predictable pharmacokinetics and lower hemorrhagic risk. Unfractionated heparin (UFH) may be used when rapid reversal is anticipated (e.g., before neurosurgery).
• Maintenance phase: Transition to oral anticoagulants for 3–12 months, depending on etiology. Options include:
  • Vitamin K antagonists (warfarin) with target INR 2.0–3.0.
  • Direct oral anticoagulants (DOACs) – rivaroxaban, apixaban, or dabigatran – increasingly supported by recent trials (e.g., RE-SPECT CVT) showing non‑inferiority to warfarin <sup>[3]</sup>.

Management of intracranial hypertension

• Head‑of‑bed elevation (30°), adequate hydration, and avoidance of excessive Valsalva.
• Acetazolamide (500 mg PO q8h) can reduce CSF production in selected patients.
• Therapeutic lumbar puncture may be considered for symptomatic relief, but repeat procedures are limited by risk of herniation.

Seizure control

• Empiric antiepileptic drugs (AEDs) such as levetiracetam or valproic acid are started if a seizure occurs; continuation for 3–6 months after the event is typical.

Endovascular and surgical interventions

Reserved for patients who deteriorate despite optimal anticoagulation or have extensive clot burden causing mass effect.

• Mechanical thrombectomy – catheter‑directed aspiration or stent‑retriever techniques; growing evidence of benefit in severe cases.
• Local thrombolysis – infusion of tissue plasminogen activator (tPA) via a microcatheter; used when clot is extensive but carries bleeding risk.
• Decompressive hemicraniectomy – indicated for large hemorrhagic infarcts with impending herniation.

Lifestyle and supportive measures

• Smoking cessation, weight management, and regular physical activity.
• Hydration—particularly during travel or periods of immobility.
• Education on medication adherence and signs of recurrence.

Living with Dural Venous Sinus Thrombosis

Recovery varies; many patients regain near‑normal function, but some experience persistent neurological deficits or chronic headaches. Practical strategies include:

1. Medication management – Use a pill organizer, set alarms, and keep a medication list for all healthcare providers.
2. Follow‑up imaging – Repeat MRV or CTV at 3–6 months to assess recanalization; frequency guided by neurologist.
3. Rehabilitation – Physical, occupational, and speech therapy as indicated; early involvement improves outcomes.
4. Headache diary – Record intensity, triggers, and response to analgesics; share with your physician.
5. Vaccinations – Annual influenza and COVID‑19 vaccines reduce infection‑related clot risk.
6. Pregnancy counseling – Women planning pregnancy should discuss anticoagulation plans with a high‑risk obstetrician; LMWH is usually continued throughout gestation.

Prevention

Because many risk factors are modifiable, prevention focuses on minimizing clot‑forming stimuli:

• Maintain adequate hydration – Aim for at least 2 L of fluid daily, more during hot weather or travel.
• Limit estrogen exposure – If possible, choose non‑hormonal contraception; discuss alternatives with your clinician.
• Manage chronic diseases – Tight control of diabetes, hypertension, and hyperlipidemia.
• Screen for thrombophilia – Especially if there is a personal or strong family history of venous thromboembolism.
• Mobilize early – After surgery or prolonged bed rest, use compression stockings and ambulate as soon as safely possible.
• Weight control and smoking cessation – Both reduce baseline hypercoagulability.

Complications

If left untreated or inadequately managed, DVST can lead to serious sequelae:

• Venous infarction – Often hemorrhagic, leading to focal neurological loss.
• Brain herniation – From massive edema, a life‑threatening emergency.
• Chronic intracranial hypertension – Causes persistent headaches, visual field loss, and papilledema.
• Seizure disorder – May become refractory, requiring long‑term AED therapy.
• Persistent neurocognitive deficits – Memory, attention, or executive function impairments.
• Recurrent thrombosis – Especially if underlying pro‑thrombotic condition is not identified or treated.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Cerebral venous sinus thrombosis.” Updated 2023. https://www.mayoclinic.org
2. WHO. “Global burden of cerebrovascular disease.” 2022. https://www.who.int
3. Goraya TY, et al. “Direct oral anticoagulants for cerebral venous thrombosis: RE‑SPECT CVT trial.” *Lancet Neurology*, 2021.
4. Stam J. “Thrombosis of the cerebral veins and sinuses.” *New England Journal of Medicine*, 2020;382:1256‑1266.

```